Health Care • Medical/Dental Instruments
$85.27 ▲ +2.40
(+2.90%)
MKT CAP: $1.95B • VOL: 300.1K
52W L $78 52W H $118
LMAT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $249.6M | $219.9M | $193.5M |
| YoY Revenue Growth % | +13.5% | +13.6% | — |
| Gross Profit | $178.5M | $150.9M | — |
| Gross Margin % | 71.5% | 68.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $67.9M | $52.3M | $36.7M |
| Operating Margin % | 27.2% | 23.8% | 19.0% |
| Net Income (GAAP) | $57.7M | $44.0M | $30.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $81.3M | $44.1M | $36.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $81.3M | $44.1M | $36.8M |
| FCF Margin % | 32.6% | 20.1% | 19.0% |
| Return on Invested Capital (ROIC %) | 14.7% | 13.2% | — |
| Cash & Short-Term Equivalents | $28.2M | $25.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $393.5M | $337.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LMAT.